SCHEMBL6792845

SCHEMBL6792845

CCCCC1Cc2c(n[nH]c2C(N)=O)-c2ccc(O)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CCNA1 P78396 1/20 0.37
CYP19A1 P11511 4/20 0.35
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
USP2 O75604 2/20 0.33
ALOX15 P16050 2/20 0.33
ALOX12 P18054 2/20 0.33
CHEK1 O14757 1/20 0.33
POLB P06746 1/20 0.33
KDM4E B2RXH2 2/20 0.31
HSD17B10 Q99714 2/20 0.31
ALPL P05186 1/20 0.31
CLK1 P49759 1/20 0.31
GLA P06280 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793173 0.79 MEN1 (0.43) MEN1KMT2AUSP2ALOX15ALOX12
SCHEMBL6792195 0.71 MEN1 (0.46) MEN1KMT2AALOX15ALOX12CHEK1
SCHEMBL6793552 0.69 CCNA2 (0.54) CCNA2CDK2CCNA1MEN1KMT2A
SCHEMBL6795304 0.66 CCNA2 (0.54) CCNA2CDK2CCNA1MEN1KMT2A
SCHEMBL6792843 0.65 HSP90AA1 (0.39) CCNA2CDK2CCNA1CYP19A1JAK2
SCHEMBL6787520 0.63 JAK2 (0.37) JAK2JAK1TYK2JAK3CHEK1
SCHEMBL13631611 0.62 HCAR2 (0.54) HCAR2
SCHEMBL13631613 0.62 HCAR2 (0.54) HCAR2
SCHEMBL4478198 0.62 HCAR2 (0.54) HCAR2
SCHEMBL6788929 0.59 MEN1 (0.54) MEN1KMT2AUSP2ALOX15ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 MKNK2, MAPKAPK2, MAP3K2 CCNA2 270/4885CDK2 29/4885CCNA1 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.